Latest Cash Runway News

Mont Royal Resources is on track to release an updated Preliminary Economic Assessment for its Ashram Rare Earths project in May, with a promising geological review highlighting the BD-Zone as a key area for resource expansion. The company also secured a strategic non-binding MOU with Saguenay Port Authority and extended funding for critical infrastructure.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

Arafura Rare Earths has locked in binding cornerstone equity agreements worth approximately A$230 million, bolstering its path to a final investment decision for the Nolans Project. The company also acquired critical camp infrastructure and is progressing technology development and offtake negotiations amid supportive government frameworks.

Belararox has ramped up drilling at its TMT Project in Argentina, unveiling a significant high-grade silver zone at Toro Central and expanding its landholding with the El Faro acquisition. Meanwhile, exploration in Botswana gears up with a major airborne electromagnetic survey, and the company contemplates divesting its Australian Belara Project to sharpen focus on core assets.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

CONNEQT Health’s Pulse device sales surged to a $7 million annualised run-rate despite a temporary supply hiccup, while the company manages a tight cash runway supported by new R&D loans and related-party funding.

Amplia Therapeutics reported mature ACCENT trial data showing improved survival and multiple complete responses with narmafotinib, alongside a GMP production milestone and CFO appointment.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

Mammoth Minerals reported significant shallow gold intercepts at its Excelsior Springs project in Nevada, expanded its landholding with the Imperial Gold Project acquisition, and completed the Paterson divestment, positioning itself for further exploration growth.

Noble Helium has secured $12 million in a two-tranche placement to advance its North Rukwa helium project in Tanzania, positioning itself as a key player amid a global helium supply disruption caused by Middle East conflicts.

Kingfisher Mining has confirmed high-grade copper-gold mineralisation at Copper Blow, secured a processing deal with Broken Hill Mines, and completed its Gascoyne REE divestment, sharpening its NSW focus.

Miramar Resources has completed a 19-hole RC drilling program at its Gidji JV Gold Project, revealing extensive shallow gold mineralisation including high-grade hits. The company also progressed project sales and acquisitions, supported by a $1.49 million capital raise and board reshuffle.